申请人:——
公开号:US20030229078A1
公开(公告)日:2003-12-11
A new method to synthesize the platelet-activating factor antagonist which is a derivative of thienotriazolodiazepene, tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methosy-4 phenyl carbamoyl)-9 pyrido[4,3-:4,5] thieno[3,2-f] triazolo-1,2,4 [4,3-&agr;] diazepine-1,4] (1) is disclosed. The compound synethesized by this new method has been designated “LAU-8080” which has the same structure as the compound currently named in the literature as “BN-50730.” LAU-8080 was shown to prevent photoreceptor cell death, inhibit pathological neovascularization in the retina, and minimize the loss of neurons due to ischemic-reperfusion damage due to stroke. Thus LAU-8080 can be used to treat the retinal diseases of age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy. It can also be used to minimize the neuronal damage due to stroke.
1
一种新的合成血小板活化因子拮抗剂的方法被披露,该方法是噻唑三唑二唑啉的衍生物,四氢-4,7,8,10 甲基-1(氯-2 苯基)-6(甲氧基-4 苯基羰胺基)-9 吡啶[4,3-:4,5] 噻吩[3,2-f] 三唑-1,2,4 [4,3-&agr;] 二唑啉-1,4](1)。通过这种新方法合成的化合物被命名为“LAU-8080”,其结构与当前文献中命名为“BN-50730”的化合物相同。已经证明LAU-8080能够预防光感受器细胞死亡,抑制视网膜病理性新生血管形成,并减少因缺血再灌注损伤导致的神经元丧失。因此,LAU-8080可用于治疗与年龄相关性黄斑变性、视网膜色素变性和糖尿病性视网膜病变相关的视网膜疾病。它还可以用于减少因中风导致的神经元损伤。